Research programme: antimalarials - GlaxoSmithKline/MMV
Alternative Names: Amodiaquine analogues - GlaxoSmithKline/MMV; Azithromycin-based antimalarials - GlaxoSmithKline/MMV; carboxamides - GlaxoSmithKline/MMV; Cysteine protease inhbitors - GlaxoSmithKline/MMV; Enoyl-ACP reductase inhibitors - GlaxoSmithKline/MMV; GSK-369796; GW 308678; Isoquine analogues - GlaxoSmithKline/MMVLatest Information Update: 02 Oct 2021
At a glance
- Originator GlaxoSmithKline; Medicines for Malaria Venture
- Developer GSK; Medicines for Malaria Venture; University of California at San Francisco
- Class Aminoquinolines; Erythromycins; Pyridones
- Mechanism of Action Cysteine endopeptidase inhibitors; Dihydroorotate dehydrogenase inhibitors; Electron transport complex I inhibitors; Enoyl ACP reductase inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in Spain
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA
- 18 Apr 2011 Preclinical development is ongoing in the US and Spain